Financial Consulate’s ANI Pharmaceuticals ANIP Stock Holding History

Financial Consulate’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$218	Buy	+3	New	+$231	﹤0.01%	1671

Other funds holding ANIP

Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

Kendall Capital Management Rockville, Maryland $605M AUM 38.16% 1-Year Est. Return

Samalin Investment Counsel Chappaqua, New York $319M AUM 12.97% 1-Year Est. Return

Financial Consulate's ANIP Position: Q3 2026 in Review

Financial Consulate opened a new position in ANI Pharmaceuticals (ANIP) in Q3 2026: 3 shares worth $218. The stake represents ﹤0.01% of the portfolio and ranks #1671 among its holdings.

39 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

Financial Consulate held 3 shares of ANI Pharmaceuticals worth $218 as of Q3 2026.
ANI Pharmaceuticals was a new Financial Consulate position in Q3 2026.
ANI Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1671 holding.
39 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.